0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Articles |

Thyrotoxic Bone Disease in Women: A Potentially Reversible Disorder

Terrence Diamond, MB; Julie Vine; Richard Smart, PhD; and Patrick Butler, MB
[+] Article and Author Information

From St George Hospital, Sydney, New South Wales, Australia. Requests for Reprints: Terrence Diamond, MB, Department of Endocrinology, St George Hospital, Kogarah, New South Wales, 2217, Australia.


Copyright ©2004 by the American College of Physicians


Ann Intern Med. 1994;120(1):8-11. doi:10.7326/0003-4819-120-1-199401010-00002
Text Size: A A A

Objective: To measure changes in spinal and femoral neck bone mineral densities in patients treated for Graves thyrotoxicosis.

Design: Cohort study.

Setting: Tertiary care center.

Patients: Fifteen women with active Graves thyrotoxicosis. Six patients were premenopausal and nine were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine, suppressed serum thyroid-stimulating hormone, and an elevated technetium-99m pertechnetate thyroid scan. A control group of 15 healthy volunteers matched for age, sex, and menopausal status were followed during the same period.

Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry at baseline and after 12 months of antithyroid therapy when euthyroidism had been achieved.

Results: After 12 months of therapy, total serum thyroxine, total serum triiodothyronine, serum alkaline phosphatase, and serum bone Gla-protein activities had returned to normal in all patients (P < 0.001 for all comparison between initial and final biochemical measurements). During this interval, the mean lumbar spine bone mineral increased from an initial value of 1.01 g/cm2 to 1.07 g/cm2, an increase of 6.6% per year (95% CI, 3.6% to 9.6%) (P < 0.001 compared with controls). Increases in femoral neck (1.2%/y; CI, −2.1% to 4.5%; P = 0.2 compared with controls) and femoral trochanter bone mineral (3.2%/y; CI, 2.4% to 8.7%; P = 0.2 compared with controls) were not statistically significant. Using forced-entry multiple regression analysis, the severity of the thyrotoxicosis was independently associated with the percentage increment in lumbar spine bone mineral density after 12 months of antithyroid therapy.

Conclusion: Effective treatment of Graves thyrotoxicosis was associated with increases in lumbar spine and femoral neck bone mineral. Although the changes in bone mineral were modest, our data suggest that thyrotoxic bone loss may be a reversible disorder.

Figures

Grahic Jump Location
Figure 1.
Individual bone mineral values of the lumbar spine (squares) and femoral neck (circles) before (open symbols) and after 12 months of antithyroid therapy (closed symbols) in patients with Graves thyrotoxicosis, expressed as a percentage of age- and sex-matched controls.

The horizontal bars represent the mean values of the two groups.

Grahic Jump Location
Grahic Jump Location
Figure 2.
Individual bone mineral values of the lumbar spine (squares), femoral neck (circles), Ward triangle (diamonds), and trochanter in patients with Graves thyrotoxicosis (closed symbols) and in controls (open symbols), expressed as a percentage change of bone mineral over a 12-month period.
Grahic Jump Location

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Related Point of Care
Topic Collections
Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)